Cerebral Fungal Infection in Pediatric Cancer Patients

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. 1.
   Nieves DJ, Antonio C. Recent studies on invasive fungal diseases in children and adolescents: an update. Curr Fungal Infect Rep. 2014;8:56–66.CrossRefGoogle Scholar
2. 2.
   Benjamin Jr DK, Miller WC, Bayliff S, et al. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J. 2002;21:227–34.CrossRefPubMedGoogle Scholar
3. 3.
   Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer. 2010;55:1103–7.CrossRefPubMedGoogle Scholar
4. 4.
   Groll AH, Kurz M, Schneider W, et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses. 1999;42:431–42.CrossRefPubMedGoogle Scholar
5. 5.
   Hale KA, Shaw PJ, Dalla-Pozza L, et al. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol. 2010;149:263–72.CrossRefPubMedGoogle Scholar
6. 6.
   Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 2000;26:999–1004.CrossRefPubMedGoogle Scholar
7. 7.
   Kaya Z, Gursel T, Kocak U, et al. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer. 2009;52:470–5.CrossRefPubMedGoogle Scholar
8. 8.
   Kobayashi R, Kaneda M, Sato T, et al. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol. 2008;30:886–90.CrossRefPubMedGoogle Scholar
9. 9.
   Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–66.CrossRefPubMedGoogle Scholar
10. 10.
    Mor M, Gilad G, Kornreich L, et al. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer. 2011;56:1092–7.CrossRefPubMedGoogle Scholar
11. 11.
    Rosen GP, Nielsen K, Glenn S, et al. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol. 2005;27:135–40.CrossRefPubMedGoogle Scholar
12. 12.
    Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–9.CrossRefPubMedGoogle Scholar
13. 13.
    Besnard M, Hartmann O, Valteau-Couanet D, et al. Systemic Candida infection in pediatric BM autotransplantation: clinical signs, outcome and prognosis. Bone Marrow Transplant. 1993;11:465–70.PubMedGoogle Scholar
14. 14.
    Dvorak CC, Steinbach WJ, Brown JM, et al. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621–9.CrossRefPubMedGoogle Scholar
15. 15.
    Flynn PM, Marina NM, Rivera GK, et al. Candida tropicalis infections in children with leukemia. Leuk Lymphoma. 1993;10:369–76.CrossRefPubMedGoogle Scholar
16. 16.
    Vogiatzi L, Ilia S, Sideri G, et al. Invasive candidiasis in pediatric intensive care in Greece: a nationwide study. Intensive Care Med. 2013;39:2188–95.CrossRefPubMedGoogle Scholar
17. 17.
    Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J Pediatr Hematol Oncol. 2009;31:911–9.CrossRefPubMedGoogle Scholar
18. 18.
    Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J. 2004;23:635–41.CrossRefPubMedGoogle Scholar
19. 19.
    Castagnola E, Faraci M, Moroni C, et al. Invasive mycoses in children receiving hemopoietic SCT. Bone Marrow Transplant. 2008;41 Suppl 2:S107–11.CrossRefPubMedGoogle Scholar
20. 20.
    MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children’s hospital. Clin Infect Dis. 1998;26:642–5.CrossRefPubMedGoogle Scholar
21. 21.
    Mahul P, Piens MA, Guyotat D, et al. Disseminated Geotrichum capitatum infection in a patient with acute myeloid leukemia. Mycoses. 1989;32:573–7.CrossRefPubMedGoogle Scholar
22. 22.
    Menezes EA, Marinho JA, Angelo MR, et al. Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceara, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54:1–3.CrossRefPubMedGoogle Scholar
23. 23.
    Severo CB, Xavier MO, Gazzoni AF, et al. Cryptococcosis in children. Paediatr Respir Rev. 2009;10:166–71.CrossRefPubMedGoogle Scholar
24. 24.
    Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711–6.CrossRefPubMedGoogle Scholar
25. 25.
    Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis. 1999;29:1210–9.CrossRefPubMedGoogle Scholar
26. 26.
    Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781–803. quiz 804–5.CrossRefPubMedGoogle Scholar
27. 27.
    Dotis J, Iosifidis E, Roilides E. Central nervous system aspergillosis in children: a systematic review of reported cases. Int J Infect Dis. 2007;11:381–93.CrossRefPubMedGoogle Scholar
28. 28.
    Kourkoumpetis TK, Desalermos A, Muhammed M, et al. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore). 2012;91:328–36.CrossRefGoogle Scholar
29. 29.
    Odio CM, Navarrete M, Carrillo JM, et al. Disseminated histoplasmosis in infants. Pediatr Infect Dis J. 1999;18:1065–8.CrossRefPubMedGoogle Scholar
30. 30.
    Fischer GB, Mocelin H, Severo CB, et al. Histoplasmosis in children. Paediatr Respir Rev. 2009;10:172–7.CrossRefPubMedGoogle Scholar
31. 31.
    Bariola JR, Perry P, Pappas PG, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis. 2010;50:797–804.CrossRefPubMedGoogle Scholar
32. 32.
    Drake KW, Adam RD. Coccidioidal meningitis and brain abscesses: analysis of 71 cases at a referral center. Neurology. 2009;73:1780–6.CrossRefPubMedGoogle Scholar
33. 33.
    Fanella S, Skinner S, Trepman E, et al. Blastomycosis in children and adolescents: a 30-year experience from Manitoba. Med Mycol. 2011;49:627–32.PubMedGoogle Scholar
34. 34.
    Fisher BT, Chiller TM, Prasad PA, et al. Hospitalizations for coccidioidomycosis at 41 children’s hospitals in the United States. Pediatr Infect Dis J. 2010;29:243–7.CrossRefPubMedGoogle Scholar
35. 35.
    Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–70.CrossRefPubMedGoogle Scholar
36. 36.
    Zaoutis TE, Roilides E, Chiou CC, et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J. 2007;26:723–7.CrossRefPubMedGoogle Scholar
37. 37.
    Raman Sharma R. Fungal infections of the nervous system: current perspective and controversies in management. Int J Surg. 2010;8:591–601.CrossRefPubMedGoogle Scholar
38. 38.
    Gamaletsou MN, Sipsas NV, Roilides E, et al. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep. 2012;14:423–34.CrossRefPubMedGoogle Scholar
39. 39.
    Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000;37:169–79.CrossRefPubMedGoogle Scholar
40. 40.
    Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology. 1985;35:1654–7.CrossRefPubMedGoogle Scholar
41. 41.••
    Groll AH, Schrey D, Tragiannidis A, et al. Invasive aspergillosis in children and adolescents. Curr Pharm Des. 2013;19:3545–68. This is a recent comprehensive review on invasive aspergillosis which focuses on pediatric patients.CrossRefPubMedGoogle Scholar
42. 42.
    McCullers JA, Vargas SL, Flynn PM, et al. Candidal meningitis in children with cancer. Clin Infect Dis. 2000;31:451–7.CrossRefPubMedGoogle Scholar
43. 43.
    Blyth CC, Palasanthiran P, O’Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics. 2007;119:772–84.CrossRefPubMedGoogle Scholar
44. 44.••
    Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–38. These are first international guidelines on the management of fever and neutropenia in pediatric cancer patients.CrossRefPubMedGoogle Scholar
45. 45.
    Pollack E, Bhaya A, Law M. Differentiating intracranial aspergillosis from a high grade glioma using MRI and MR spectroscopic imaging. J Neuroimaging. 2007;17:361–6.CrossRefPubMedGoogle Scholar
46. 46.
    Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol. 1994;162:155–9.CrossRefPubMedGoogle Scholar
47. 47.
    Nickerson JP, Richner B, Santy K, et al. Neuroimaging of pediatric intracranial infection—part 2: TORCH, viral, fungal, and parasitic infections. J Neuroimaging. 2012;22:e52–63.CrossRefPubMedGoogle Scholar
48. 48.
    Lindsley MD. The future of fungal serology. Curr Fungal Infect Rep 2013;in press.Google Scholar
49. 49.••
    Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–40. These are the first international guidelines for the prevention and management of invasive fungal diseases in pediatric cancer patients.CrossRefPubMedGoogle Scholar
50. 50.
    De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.CrossRefPubMedCentralPubMedGoogle Scholar
51. 51.
    Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–9.CrossRefPubMedGoogle Scholar
52. 52.
    Roilides E, Pavlidou E, Papadopoulos F, et al. Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. Pediatr Nephrol. 2003;18:450–3.PubMedGoogle Scholar
53. 53.
    Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 2002;40:1496–9.CrossRefPubMedCentralPubMedGoogle Scholar
54. 54.
    Oz Y, Kiraz N. Diagnostic methods for fungal infections in pediatric patients: microbiological, serological and molecular methods. Expert Rev Anti Infect Ther. 2011;9:289–98.CrossRefPubMedGoogle Scholar
55. 55.
    Mikulska M, Furfaro E, Del Bono V, et al. (1-3)-beta-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis. 2013;56:1511–2.CrossRefPubMedGoogle Scholar
56. 56.
    Smith PB, Benjamin Jr DK, Alexander BD, et al. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol. 2007;14:924–5.CrossRefPubMedCentralPubMedGoogle Scholar
57. 57.
    Hummel M, Spiess B, Kentouche K, et al. Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J Clin Microbiol. 2006;44:3989–93.CrossRefPubMedCentralPubMedGoogle Scholar
58. 58.
    Skladny H, Buchheidt D, Baust C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol. 1999;37:3865–71.PubMedCentralPubMedGoogle Scholar
59. 59.
    Landlinger C, Preuner S, Baskova L, et al. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia. 2010;24:2032–8.CrossRefPubMedGoogle Scholar
60. 60.
    Cesaro S, Stenghele C, Calore E, et al. Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases. Mycoses. 2008;51:497–504.CrossRefPubMedGoogle Scholar
61. 61.•
    Reinwald M, Buchheidt D, Hummel M, et al. Diagnostic performance of an Aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis. PLoS One. 2013;8:e56706. This is an important study on PCR-based Aspergillus detection in cerebrospinal fluid samples. The study includes a large number of patients, and the results may have an important impact on the diagnostic procedure in suspected IFD affecting the CNS.CrossRefPubMedCentralPubMedGoogle Scholar
62. 62.
    Dornbusch HJ, Groll A, Walsh TJ. Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect. 2010;16:1328–34.CrossRefPubMedGoogle Scholar
63. 63.••
    Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26:493–500. This is a key review on the emergence of azole resistance in Aspergillus fumigatus which has important implications for future prevention and treatment strategies of invasive aspergillosis.CrossRefPubMedGoogle Scholar
64. 64.
    Sorensen J, Becker M, Porto L, et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses. 2006;49 Suppl 1:31–6.CrossRefPubMedGoogle Scholar
65. 65.
    Lescar J, Meyer I, Akshita K, et al. Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole. J Antimicrob Chemother 2014.Google Scholar
66. 66.
    Montesinos I, Dodemont M, Lagrou K, et al. New case of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in Belgium. J Antimicrob Chemother 2014.Google Scholar
67. 67.
    Spiess B, Postina P, Reinwald M, et al. Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. PLoS One. 2014;9:e103113.CrossRefPubMedCentralPubMedGoogle Scholar
68. 68.
    Antinori S, Corbellino M, Meroni L, et al. Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect. 2013;66:218–38.CrossRefPubMedGoogle Scholar
69. 69.
    McGinnis MR. Detection of fungi in cerebrospinal fluid. Am J Med. 1983;75:129–38.CrossRefPubMedGoogle Scholar
70. 70.
    Lehrnbecher T, Aplenc R, Rivas Pereira F, et al. Variations in non-pharmacological anti-infective measures in childhood leukemia—results of an international survey. Haematologica. 2012;97:1548–52.CrossRefPubMedCentralPubMedGoogle Scholar
71. 71.
    Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol. 2001;66:257–62.CrossRefPubMedGoogle Scholar
72. 72.•
    Akan H, Antia VP, Kouba M, et al. Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. J Antimicrob Chemother. 2013;68 Suppl 3:iii5–16. This recent article nicely reviews the practical aspects of preventing fungal infections in hematologic cancer patients.PubMedGoogle Scholar
73. 73.
    Charalampos D, Athanassiadou F. Primary and secondary antifungal prophylaxis in the immunocompromised child: where do we stand? Curr Fungal Infect Rep. 2013;7:1–7.CrossRefGoogle Scholar
74. 74.
    Science M, Robinson PD, MacDonald T, et al. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61:393–400.CrossRefPubMedGoogle Scholar
75. 75.
    Bochennek K, Tramsen L, Schedler N, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect. 2011;17:1868–74.CrossRefPubMedGoogle Scholar
76. 76.
    Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant. 1999;24:1089–93.CrossRefPubMedGoogle Scholar
77. 77.
    Roman E, Osunkwo I, Militano O, et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer. 2008;50:325–30.CrossRefPubMedGoogle Scholar
78. 78.
    van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.CrossRefPubMedGoogle Scholar
79. 79.
    Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.CrossRefPubMedCentralPubMedGoogle Scholar
80. 80.
    Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin. 2013;29 Suppl 4:13–8.CrossRefPubMedGoogle Scholar
81. 81.
    Black KE, Baden LR. Fungal infections of the CNS: treatment strategies for the immunocompromised patient. CNS Drugs. 2007;21:293–318.CrossRefPubMedGoogle Scholar
82. 82.
    S. CK, Bariola JR. Current antifungal agents for treatment of central nervous system infections. Curr Fungal Infect Rep 2014;8:146–52Google Scholar
83. 83.
    Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641–5.CrossRefPubMedGoogle Scholar
84. 84.
    Mikulska M, Novelli A, Aversa F, et al. Voriconazole in clinical practice. J Chemother. 2012;24:311–27.CrossRefPubMedGoogle Scholar
85. 85.
    Morris AM. Review: voriconazole for prevention or treatment of invasive fungal infections in cancer with neutropenia. Ann Intern Med. 2014;161:JC8.CrossRefPubMedGoogle Scholar